MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Abstract OT1-1-06: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs12-ot1-1-06 ◽

2012 ◽

Cited By ~ 1

Author(s):

JP Crown ◽

B Moulton ◽

N O'Donovan

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

10.1158/0008-5472.sabcs13-p2-16-10 ◽

2013 ◽

Author(s):

EA Perez ◽

JM López-Vega ◽

L Del Mastro ◽

T Petit ◽

C Zamagni ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

10.1158/1538-7445.am2020-ct212 ◽

2020 ◽

Author(s):

John Crown ◽

William Jacot ◽

Denis M. Collins ◽

Linda Coate ◽

Anna Saetersdal ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1128881.585979 ◽

2008 ◽

Author(s):

Carmelo Bengala

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3132 ◽

2009 ◽

Cited By ~ 3

Author(s):

K Najagami ◽

K Inoue ◽

M Mizutani ◽

Y Hozumi ◽

Y Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iii Study ◽

Trastuzumab Monotherapy ◽

Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet)

Annals of Oncology ◽

10.1016/s0923-7534(20)32976-8 ◽

2012 ◽

Vol 23 ◽

pp. ix142

Author(s):

M. Andersson ◽

J.M. Lopez-Vega ◽

L. Del Mastro ◽

T. Petit ◽

L. Mitchell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.1041 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 1041-1041

Author(s):

V. Lorusso ◽

F. Giotta ◽

R. Bordonaro ◽

E. Maiello ◽

S. Del Prete ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Breast Cancer Research ◽

10.1186/s13058-016-0773-6 ◽

2016 ◽

Vol 18 (1) ◽

Cited By ~ 27

Author(s):

Edith A. Perez ◽

José Manuel López-Vega ◽

Thierry Petit ◽

Claudio Zamagni ◽

Valerie Easton ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Safety And Efficacy ◽

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90842-7 ◽

2004 ◽

Vol 2 (3) ◽

pp. 125-126 ◽

Cited By ~ 20

Author(s):

J.M Extra ◽

F Cognetti ◽

D Maranichi ◽

R Snyder ◽

L Mauriac ◽

...

Keyword(s):

Breast Cancer ◽

Multicentre Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.

10.1158/0008-5472.sabcs-2155 ◽

2009 ◽

Author(s):

A Lorenzo ◽

A Modolell ◽

P Valero ◽

L Murillo ◽

JM García-Bueno ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽